- Home
- PRLD vs QNCX Comparison
PRLD vs QNCX Comparison
Compare PRLD & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- QNCX
- Stock Information
- Founded
- PRLD 2016
- QNCX 2012
- Country
- PRLD United States
- QNCX United States
- Employees
- PRLD N/A
- QNCX N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRLD Health Care
- QNCX Health Care
- Exchange
- PRLD Nasdaq
- QNCX Nasdaq
- Market Cap
- PRLD 50.1M
- QNCX 43.2M
- IPO Year
- PRLD 2020
- QNCX 2019
- Fundamental
- Price
- PRLD $0.89
- QNCX $1.04
- Analyst Decision
- PRLD Strong Buy
- QNCX Strong Buy
- Analyst Count
- PRLD 2
- QNCX 5
- Target Price
- PRLD $4.50
- QNCX $8.00
- AVG Volume (30 Days)
- PRLD 137.5K
- QNCX 611.7K
- Earning Date
- PRLD 05-06-2025
- QNCX 05-13-2025
- Dividend Yield
- PRLD N/A
- QNCX N/A
- EPS Growth
- PRLD N/A
- QNCX N/A
- EPS
- PRLD N/A
- QNCX N/A
- Revenue
- PRLD $7,000,000.00
- QNCX N/A
- Revenue This Year
- PRLD N/A
- QNCX N/A
- Revenue Next Year
- PRLD N/A
- QNCX N/A
- P/E Ratio
- PRLD N/A
- QNCX N/A
- Revenue Growth
- PRLD N/A
- QNCX N/A
- 52 Week Low
- PRLD $0.61
- QNCX $0.51
- 52 Week High
- PRLD $6.80
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- PRLD 51.42
- QNCX 49.33
- Support Level
- PRLD $0.77
- QNCX $0.93
- Resistance Level
- PRLD $1.00
- QNCX $1.06
- Average True Range (ATR)
- PRLD 0.11
- QNCX 0.11
- MACD
- PRLD -0.01
- QNCX 0.02
- Stochastic Oscillator
- PRLD 37.18
- QNCX 76.19
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.